retatrutide vs semaglutide Tirzepatide vs Retatrutide: 2026 Chicago Guide GLP-1 Comparison 2026: Semaglutide vs

Aggregates, peptide-related impurities, contaminants and formulation components may alter immune recognition

A novel triple therapy, retatrutide, could continue the string of game-changing metabolic agents that began with semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist for type 2 diabetes and obesity, and continued with tirzepatide, a dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist

These drugs reached patients with diabetes long before the science was ready to ask them to protect the brain

subcutaneous semaglutide (up to a dose of 2.4 mg weekly), or dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonists e.g

If it was a digestive side effect, you name it, and I had it